KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation von Jänne, P.A., Rybkin, I.I., Spira, A.I., Riely, G.J., Papadopoulos, K.P., Sabari, J.K., Johnson, M.L., Heist, R.S., Bazhenova, L., Barve, M., Pacheco, J.M., Leal, T.A., Velastegui, K., Cornelius, C., Olson, P., Christensen, J.G., Kheoh, T., Chao, R.C., Ou, S.H.I.

Volltext

2879 High prevalent BRAF alterations and tert promoter mutations in papillary thyroid carcinoma von Wang, K, Ganesan, S, Johnson, A, Sharman, J.P, Chachoua, A, Hirshfield, K, Aisner, J, Yelensky, R, Lipson, D, Elvin, J.A, Chmielecki, J, Stephens, P.J, Ross, J.S, Miller, V.A, Ou, S.H.I, Ali, S.M

Volltext

What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC) von Drilon, A., Li, G., Dogan, S., Gounder, M., Shen, R., Arcila, M., Wang, L., Hyman, D.M., Hechtman, J., Wei, G., Cam, N.R., Christiansen, J., Luo, D., Maneval, E.C., Bauer, T., Patel, M., Liu, S.V., Ou, S.H.I., Farago, A., Shaw, A., Shoemaker, R.F., Lim, J., Hornby, Z., Multani, P., Ladanyi, M., Berger, M., Katabi, N., Ghossein, R., Ho, A.L.

Volltext

Safety and preliminary clinical activity of NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1 fusion-positive solid tumors von Drilon, A., Besse, B., Camidge, D.R., Ou, S.H.I., Gadgeel, S.M., Johnson, M.L., Calles, A., de Miguel, M.J., Spira, A.I., Felip, E., Lopes, G., van der Wekken, A.J., Elamin, Y.Y., Green, J., Sun, Y., Soglia, J., Zhu, V.W., Lin, J.J.

Volltext

KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation von Johnson, M.L., Ou, S.H.I., Barve, M., Rybkin, I.I., Papadopoulos, K.P., Leal, T.A., Velastegui, K., Christensen, J.G., Kheoh, T., Chao, R.C., Weiss, J.

Volltext

Corrigendum to “Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy”... von Liu, S.V., De Braud, F., Drilon, A., Doebele, R.C., Patel, M.R., Cho, B.C., Ahn, M.J., Chiu, C.H., Farago, A.F., Goto, K., Lee, J., Ohe, Y., Ou, S.H.I., Cassier, P., Tan, D.S.W., Otterson, G.A., Veronese, L., Osborne, S., Simmons, B., Siena, S.

Volltext

Corrigendum to “Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy”... von Liu, S.V., De Braud, F., Drilon, A., Doebele, R.C., Patel, M.R., Cho, B.C., Ahn, M.J., Chiu, C.H., Farago, A.F., Goto, K., Lee, J., Ohe, Y., Ou, S.H.I., Cassier, P., Tan, D.S.W., Otterson, G.A., Veronese, L., Osborne, S., Simmons, B., Siena, S.

Volltext

385P Patient reported outcomes (PROs) analysis for patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) receiving entrectinib in the global phase II STARTR... von Barlesi, F., Wolf, J., Ahn, M-J., Doebele, R.C., Paz-Ares, L., Rolfo, C., Siena, S., Seto, T., Ohe, Y., Ou, S.H.I., Krebs, M.G., Kapre, A., Piault-Louis, E., McCallum, S., Osborne, S., Aziez, A., Drilon, A.

Volltext

Effect of slaughter method and gender on the meat quality of capybara (Hydrochaeris hydrochaeris) von Oda, S.H.I, Bressan, M.C, Miguel, G.Z, Vieira, J.O, Faria, P.B, Savian, T.V, Kabeya, D.M

Volltext